BNIP2 (Gene)

Organism:

Homo sapiens

Synonyms:BCL2 interacting protein 2, BNIP-2, BNIP2, ENTREZ:663, HGNC:1083, MIM:603292, NIP2, NM_001320674, NM_001320675, NM_001368057, NM_001368058, NM_001368059, NM_001368060, NM_001368061, NM_004330, NP_001307603, NP_001307604, NP_001354986, NP_001354987, NP_001354988, NP_001354989, NP_001354990, NP_004321

Omim:OMIM:603292

Id:ENSG00000140299

Hgnc:HGNC:1083

Entrez:663

Ensembl:ENSG00000140299

Description:BCL2 interacting protein 2

This gene is a member of the BCL2/adenovirus E1B 19 kd-interacting protein (BNIP) family. It interacts with the E1B 19 kDa protein, which protects cells from virally-induced cell death. The encoded protein also interacts with E1B 19 kDa-like sequences of BCL2, another apoptotic protector. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View BNIP2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with BNIP2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using BNIP2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for BNIP2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with BNIP2.

Results found

Linked to

	Label	Description
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125956 SYK knockdown 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE95688 7 V 2 GLUTATHIONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE166536 3 V 2 DOCETAXEL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 1 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE125956 SYK knockdown 4 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE95688 7 V 2 GLUTATHIONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE166536 3 V 2 DOCETAXEL MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.